Colorectal carcinomas (CRC) harbor well-defined genetic abnormalities including aberrant activation of Wnt/β-catenin and MAPK pathways, often simultaneously. While the MAPK pathway can be targeted using potent small molecule drugs, including BRAF and MEK inhibitors, β-catenin inhibition has been historically challenging. RNA interference (RNAi) approaches have advanced to the stage of clinical viability, and are especially well-suited for transcriptional modulators such as β-catenin. In this study, we report therapeutic effects of combined targeting of these pathways with pharmacological agents. Using a recently-described tumor-selective nanoparticle containing a β-catenin-targeting RNAi trigger, in combination with the FDA-approved MEK inhibitor (MEKi) trametinib, we demonstrate synergistic tumor growth inhibition in in vivo models of CRC, melanoma and hepatocellular carcinoma. At dose levels which were insufficient to significantly impact tumor growth as monotherapies, combination regimens resulted in synergistic efficacy and complete tumor growth inhibition. Importantly, dual MEKi/RNAi therapy dramatically improved survival of mice bearing CRC liver metastases.
Introduction
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths in the United States, despite advances in early detection and targeted therapeutics (1) . Targeted therapies that have been incorporated into current standard of care regimens for CRC include anti-epidermal growth factor receptor (EGFR) monoclonal antibodies.
While EGFR is expressed in approximately 85% of CRCs (2-4), anti-EGFR antibodies were found to only confer a survival benefit to patients with wild-type KRAS and BRAF (5) (6) (7) . This leaves a large population of CRC patients with KRAS or BRAF mutations, at least 50%, ineligible for the anti-EGFR therapies cetuximab and panitumumab (8) (9) (10) . For this and other reasons (11) (12) (13) (14) (15) , refractory CRC remains a severe unmet medical need and the focus on dozens of current clinical trials.
One approach to treating this poor-prognosis population is to target effectors which are functionally downstream of KRAS and BRAF. The best characterized targets in this category are the MEK1 and MEK2 kinases, which regulate mitogen-activated protein kinases (MAPKs) via direct phosphorylation. Small molecule MEK inhibitors are already approved for BRAF-mutant melanoma, and are being evaluated for CRC as part of various combination regimens (16) . In one recent Phase I/II trial, triple-inhibition of EGFR, BRAF and MEK in BRAF-mutant CRC with panitumumab, dabrafenib and trametinib, respectively, showed improved progression-free Despite the central role of Wnt/β-catenin in CRC, pharmacological intervention of this critical pathway has proven to be challenging, and consequently there is a dearth of drug development programs that have proceeded to advanced clinical trials (29, 30) . With few exceptions, the majority of prior efforts to inhibit Wnt signaling do not target β-catenin itself, but rather target specific Wnt ligands or ligand secretory pathways, Wnt receptors or transcriptional co-activators where pathway redundancies may limit efficacy (31) . In addition to difficulty associated with direct targeting of β-catenin by conventional pharmaceutical modalities, there is also a concern that non-selectively blocking its function in normal tissues will interfere with essential homeostasis functions, particularly in the gastrointestinal tract (31) .
RNA interference technology (RNAi) is a promising alterative to small molecules and biologics for cancer therapy, as it offers the potential to potently silence any expressed gene at the mRNA level. As a drug modality, RNAi triggers are currently progressing through advanced clinical trials, where they have demonstrated sufficient therapeutic index, potency, duration and safety to enable expansion beyond their early successes targeting genetic diseases of the liver (31) . We have recently shown robust preclinical activity in Wnt-dependent tumors of diverse origin with an RNAi agent targeting CTNNB1 (32) . This agent, hereby termed DCR-BCAT, is an optimized Dicer-substrate siRNA (DsiRNA) formulated in a tumor-selective nanoparticle, and demonstrates dose-dependent silencing of β-catenin after systemic administration in preclinical tumor models (32) . A DCR-BCAT precursor featuring an earlier-generation lipid nanoparticle, DCR-MYC, achieved RNAi target engagement in diverse tumor types at well-tolerated doses in a Phase I clinical trial (33) .
To address whether inhibition of both pathways simultaneously yields benefit, we sought to evaluate a combination of the novel β-catenin RNAi-based inhibitor, DCR-BCAT and the MEK inhibitor (MEKi) trametinib (34) in multiple preclinical CRC models. Importantly, in addition to primary tumor models, metastasis models were included as this setting represents the source of most genetic complexity (35) , mortality and medical need for this disease (36) (37) (38) (39) .
This combination demonstrated synergistic efficacy in three CRC models, all with Wnt and MAPK activation. DCR-BCAT was also efficacious in models which are inherently resistant to MEKi, or which acquire resistance to MEKi after several cycles of therapy. We also investigate the potential of dual therapy in other tumor types with relevant genetics, particularly melanoma and hepatocellular carcinoma (HCC). Together, these findings suggest that direct RNAimediated inhibition of β-catenin could be an effective strategy to overcome the current limitations of combination therapy for refractory CRC and other cancers.
Materials and Methods

Materials
All DsiRNAs were synthesized by Integrated DNA Technologies, Inc. (IDT, Coralville, IA).
Primer and probe oligonucleotides used in quantitative real-time polymerase chain reaction (qRT-PCR) detection were synthesized by IDT or Life Sciences (Carlsbad, CA). Trametinib was purchased from Selleckchem (Houston, TX) with > 99% purity.
Lipid nanoparticle (LNP) and Trametinib formulations DCR-BCAT and Placebo LNPs were prepared as previously described (32) . Trametinib was dissolved in DMSO to make 5 mg/ml solution. This solution was further diluted to the appropriate concentration for p.o. dosing with the solvent mixture containing 10% Ethanol, 10% 7 Kolliphor EL and 80% water. Vehicle used in the studies was 10% DMSO in the solvent mixture.
Cell lines Human (CRC) cell lines LS411N, Ls174t and SW403, hepatocellular carcinoma cell line Hep3B and human melanoma cell line A2058 were obtained from ATCC (Manassas, VA). CRC cell lines were grown in RPMI medium supplemented with 10% fetal bovine serum (FBS). Hep3B and A2058 cells were grown in DMEM medium supplemented with 10% FBS. Mice were obtained from Harlan Laboratories (Indianapolis, IN). All cell lines used in this study were authenticated originally by ATCC using short tandem repeat analysis. Cells were expanded and frozen at low passage within one month after the receipt of the original stocks, and used within 6 passages after thawing. All cell lines were subjected to mycoplasma testing (IMPACT 1 profile by IDEXX BioResearch) before being released for use in animal studies.
Cell line-derived xenograft models β-catenin immunohistochemistry was performed as described, using a β-catenin antibody (Cell Signaling, Danvers, MA, 8480) at a concentration of 1:500 and Signal Stain DAB substrate kit (Cell Signaling, #8059). Ki67 immunochemistry was performed using an anti-Ki67 antibody (Abcam, Cambridge, MA, #ab16667) at a concentration of 1:100 and DAB under standard conditions. Image intensity quantitation was performed using Nikon Elements Software.
Western blot analysis
Tumor tissues (30-50 mg/mouse) were resuspended in lysis buffer containing protease and phosphatase inhibitors, and homogenized using a bead mill (Qiagen TissueLyser (Germantown, MD). The lysates were then clarified by centrifugation at 14,000 x g for 15 min at 4°C. Protein concentrations of the lysates were determined using the bicinchoninic acid protein assay. Equal amounts of total proteins were loaded on SDS-PAGE, transferred onto nitrocellulose membrane and probed with primary antibodies overnight at 4°C. The primary antibodies against ERK, pERK and β-catenin were obtained from Cell Signaling Technology. Blots were visualized using the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE).
Statistics
For the synergy analysis, initial assessments of group comparisons were made using ANOVA testing. Prior to ANOVA, normality was determined using the Shapiro-Wilk Test. Combination cohorts showing evidence of a difference between them and their single-agent counterparts were then further tested for synergy. Combination cohorts determined to not have synergy were tested for additivity using Tukey's test for additivity. All models for additivity included a statement for drug interaction. Further testing for additivity and synergy was performed using the Loewe method of determining a combination index (40) . Evidence of synergy was determined if the combination index was found to be less than 1.
Results
DCR-BCAT monotherapy improves the survival of mice bearing CRC liver metastases
β-catenin as a target for CRC and other tumors is strongly supported by both human genetic and functional preclinical data. DCR-BCAT, based on the formulation previously referred to as EnCore-R/CTNNB1 DsiRNA (32) is an intravenously-administered RNAi drug product. DCR-BCAT causes specific, dose-dependent silencing of CTNNB1 mRNA in preclinical murine and human tumors in vivo (32) . In xenografted human CRC tumors, robust mRNA silencing occurs throughout the tumor parenchyma, indicating efficient tumor penetration of the lipid nanoparticle ((32) and Supplementary figure S1). Importantly, DCR-BCAT is welltolerated in wild-type mice at doses as high as 10 mg/kg/week, with no elevation of liver transaminases, cumulative tissue exposure upon repeat dosing, or accelerated blood clearance that would suggest an anti-drug antibody response (Supplemental Figure S2 ). Since the target site shares complete identity between the human and murine genomes, mechanism-based and nonspecific causes of toxicity can both be considered. This tolerability profile enables a sufficient therapeutic window in preclinical models to evaluate efficacy as a monotherapy and in combination with other targeted therapeutics.
To determine the effect of DCR-BCAT monotherapy in aggressive models of CRC liver metastasis, Ls174t and LS411N cells were surgically implanted into spleen of nude mice as described previously (32) . These Wnt-activated human CRC cell lines colonize the liver and Animals were monitored daily for lethality or health deterioration to the point of moribund status, at which point they were euthanized according to IACUC protocol. In both the Ls174t model ( Figure 1C ) and the LS411N model ( Figure 1D ), DCR-BCAT treatment conferred a significant survival advantage over either DCR-Placebo or the PBS vehicle. For example, median survival of LS411N tumor-bearing mice increased by >11 weeks relative to placebo, for extended for >5 months after the last dose was administered ( Figure 1D ). These data demonstrate that silencing of CTNNB1 mRNA in an acute regimen slows the progression of both primary and metastatic lesions.
DCR-BCAT efficacy in the CRC liver metastasis model improves in combination with a MEK inhibitor
Mutations that affect the Wnt/β-catenin and/or MAPK pathways are the most common genetic lesions in CRC, and are identified in the overwhelming majority of patient biopsies collected from primary or metastatic tumors. Ls174t tumors harbor activating mutations in both the CTNNB1 and KRAS genes (41) , and therefore are expected to be sensitive to inhibition of the Wnt/β-catenin and MAPK pathways, respectively. We sought to explore if inhibition of both pathways simultaneously is advantageous in the preclinical metastatic CRC setting. Trametinib, a MEK inhibitor, was chosen as the MAPK pathway modulator based on its specificity profile and extensive preclinical and clinical data availability (34) . First, trametinib monotherapy was tested in this model and exhibited dose-dependent efficacy (Figure 2A ). Based on this singleagent trametinib data and the single-agent DCR-BCAT data ( Figure 1C ), we selected a dose level of 2 mg/kg/dose of each agent for combination therapy in the Ls174t metastasis model. We also used our experience in the single-agent settings to tune the kinetics of disease progression and treatment. Namely, we used a high cell implantation number (2 x 10 6 ) and waited three weeks after implantation before initiation of therapy. These experimental conditions serve to accelerate tumor progression and ensure that significant metastatic disease is present in the liver at the time of treatment, as shown in Figure 1A . Strikingly, the DCR-BCAT and trametinib combination provided a dramatic survival benefit compared to the single agents tested at the same dose level, improving the median survival time by 30 days vs. each single agent. The median survival was 44-45 days for monotherapy, and 74 days for dual therapy ( Figure 2B ).
Several animals in the combination cohort survived for longer than 100 days, even though the final dose was administered on Day 37. Importantly, the nanoparticle-formulated placebo DsiRNA (DCR-Placebo) offered no benefit over MEKi monotherapy alone, demonstrating that the lipid excipients or off-target activity did not contribute to the observed efficacy. These data offer proof-of-concept that direct inhibition of β-catenin is a viable strategy to sensitize CRC to MEK inhibition. 
these specific genetic backgrounds affects the response to dual-therapy, we evaluated DCR-BCAT and trametinib in two additional models ( Figure 3B-C) . While Ls174t has mutations in CTNNB1 and KRAS, LS411N carries APC/BRAF mutations and SW403 carries APC/KRAS mutations. To determine if we can achieve even greater mathematical synergy than in the Ls174t experiment ( Figure 3A) , we decreased the dose of DCR-BCAT to levels that were not expected to show efficacy in the monotherapy setting (0.1-0. would be efficacious in this setting. Figure 4A shows that xenografted SW403 tumors are initially sensitive to trametinib, but fail to respond robustly after progressive dosing cycles.
Indeed, the third dosing cycle shows little or no TGI. However, adding DCR-BCAT (3 mg/kg/dose) to the regimen yielded rapid tumor regression after the tumors have acquired the MEKi resistance ( Figure 4A ). The tumors fully recover within two weeks of dosing, but an additional cycle of combination therapy is again effective at inducing tumor regression. These data demonstrate that DCR-BCAT activity is not affected by the acquired resistance mechanisms that affect MEKi. Additionally, these data demonstrate the potential for this combination to treat established large established tumors.
To further investigate the mechanism by which DCR-BCAT overcomes trametinib resistance, we generated tumor samples at different time points corresponding to the experiment in Figure 4A Figure 4B ). These data suggest that the tumor employs modulation of Wnt/β-catenin signaling as a strategy to overcome MAPK pathway inhibition, consistent with recent data generated using a BRAF inhibitor in melanoma (47) Finally, another mechanism that has been reported to enable acquired resistance to MAPK pathway inhibitors is maintenance of the eIF4F translation initiation complex, in part through transcriptional suppression of pro-apoptotic Bcl-2 family member BMF (48) To that end, we have also two distinct mechanisms appear to be involved in sensitization to the drug combination ( Figure   4B , right panel).
In addition to acquired resistance, some tumors are inherently resistant to MEK inhibition, even if they harbor BRAF or KRAS mutations. The BRAF/PTEN mutant human melanoma cell line A2058 is insensitive to BRAF and MEK inhibition due to a stabilized elF4F translation initiation complex (48) . Unlike the acquired resistance mechanisms, A2058 innate resistance involves a point of convergence of several oncogenic pathways by dysregulating translation of signal-responsive mRNAs (48) . Using a dose level of trametinib sufficient to yield complete stasis in the CRC models (Supplementary figure S3) , 3 mg/kg/dose, only 36% TGI was achieved in subcutaneously-xenografted A2058 tumors.
DCR-BCAT monotherapy (3 mg/kg/dose) also yielded a partial response, while the combination led to complete TGI (105%, Figure 4B ). This result is confirmed by Ki67 immunohistochemistry for cell proliferation, which correlates well with the TGI data ( Figure 4D-E) . In the combination cohort, complete TGI is associated with a 70% decrease in Ki67 staining intensity, compared to a ~50% decrease in the RNAi monotherapy cohort (n=3-5/group). Therefore, RNAi therapy is not affected by multiple clinically-relevant resistance mechanisms, increasing its probability of success in combination with MEKi.
DCR-BCAT-containing regimens are efficacious in a MYC-dependent hepatocellular carcinoma model
The MYC oncogene is amplified or overexpressed in the majority of human tumors, and is particularly well-characterized as a critical driver of hepatocellular carcinoma (HCC) (49) .
Wnt/β-catenin is one of several signaling networks that regulate its expression and activity (50), and therefore RNAi-mediated silencing of CTNNB1 is highly effective in HCC preclinical models (51, 52) . Interestingly, MEK inhibition has been shown to destabilize MYC protein by regulating its ERK-dependent phosphorylation (53) . We reasoned that indirectly targeting MYC transcription and MYC stability simultaneously using DCR-BCAT and trametinib, respectively, may yield significant benefit over monotherapy. Indeed, this is the case in subcutaneouslyxenografted MYC-dependent Hep3B human HCC tumors, where 90% TGI was achieved with the combination ( Figure 5A ). To determine the relationship between MYC suppression and efficacy, MYC mRNA was measured after one dosing cycle. While DCR-BCAT and trametinib (2 mg/kg/dose of either agent) suppressed expression by 37% and 59%, respectively, the combination treatment yielded an 85% decrease in MYC compared to vehicle-treated tumors ( Figure 5B ). Finally, we sought to determine if the potentiation of RNAi-mediated efficacy by trametinib could be reproduced by targeting MYC directly with an RNAi trigger. MYC-targeting DsiRNA (33) was formulated EnCore-R, the same LNP composition used for DCR-BCAT. Strikingly, synergistic efficacy was observed with the MYC/CTNNB1 RNAi combination in Hep3B tumors, even though the dose of each RNAi trigger was reduced by half (from 2 mg/kg/dose to 1 mg/kg/dose) compared to the single-agent cohorts ( Figure 5C ). These data suggest strong potential for RNAi trigger combinations in diverse human tumors.
Discussion
RNAi is an emerging drug modality which has progressed to advanced clinical trials.
Specific target engagement in patients has been demonstrated for oligonucleotide therapeutics in cardiovascular diseases (54) , viral infection (55), rare genetic diseases (56) and cancer (57). 
For the latter, safe and efficient tumor-selective drug delivery technology remains a key limitation. LNP-based approaches have been explored to overcome the harsh tumor microenvironment, poor pharmacokinetics, and cell-trafficking properties of nucleic acidcontaining drugs. Previous RNAi candidates tested in the clinic for hepatocellular carcinoma contained derivatives of LNP formulations which were initially clinically developed for normal liver applications, not for oncology. EnCore LNP technology (32, 52) was optimized for tumor selectivity, enabling messenger RNA knockdown of well-validated oncogenic targets. β-catenin is an example of a cancer target with an abundance of human genetic evidence, but which has been difficult to drug using conventional small molecules or biologics. The translatability of preclinical efficacy results to human cancers has yet to be fully investigated for RNAi.
Numerous preclinical CRC models are sensitive to Wnt pathway blockers of varying quality and specificity (32, 58, 59) . However, several lines of evidence point to the potential benefits of blocking MAPK and Wnt signaling simultaneously. In transgenic mice, activating KRAS in a mutant APC background increases nuclear localization of β-catenin and accelerates CRC tumorigenesis (60) . Several reports demonstrated synergistic activity in vitro after targeting both pathways using combinations of small-molecule research grade compounds or marketed drugs (41, 61) , or combinations of shRNAs and small molecules (27) . In vivo proofof-concept was achieved using CRC subcutaneous xenograft models carrying inducible short hairpin RNAs (shRNAs) targeting CTNNB1 and KRAS (62) . To our knowledge, this concept has never been translated into a pharmacological approach using a specific β-catenin inhibitor prior to the current report, and has not previously been evaluated in the genetically-distinct and clinically important setting of CRC metastasis. 
In addition to primary and metastatic CRC, we also explored the combination approach in models of melanoma and HCC. The diversity of preclinical settings for which dual-therapy yields benefit suggests the potential for broad applicability in Wnt/β-catenin and MAPK driven tumors, as well as MYC-dysregulated tumors ( Figures 3, 4 and 5) . While BRAF inhibitors are frequently employed in melanoma therapy, there is some controversy regarding their potential in combination with Wnt pathway modulators. Inducible CTNNB1 shRNA expression increases sensitivity to BRAFi (47) and inhibits metastasis in melanoma (63) , but surprisingly, positive Wnt/β-catenin signaling was actually required for BRAFi-induced apoptosis (64) or associated with decreased proliferation (65) in specific contexts. These observations suggest that there may be some exceptions to the benefits of dual therapy. Indeed, one recent report strongly suggests that PTEN status in BRAF-activated melanoma affects whether Wnt signaling promotes or suppresses metastasis (66). = Additional rigorous preclinical and clinical experimentation will be necessary to determine which genetic backgrounds are most sensitive to dual therapy in melanoma.
The precise molecular interactions which enable the effects of this dual therapy approach are still emerging. Our data suggests a role for transcriptional upregulation of Wnt effector genes by MEKi, as well as regulation of the eIF4a transcription initiation complex ( Figure 4B ).
However, we cannot exclude additional mechanisms. Cross-talk between the Wnt/β-catenin and MAPK networks appears to be extremely context-dependent. For example, β-catenin has been reported to mediate resistance to BRAFi in a manner dependent on a physical interaction with transcription factor Stat3 (47) . In another report, a key negative regulator of β-catenin activity, 
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